To determine the relationship between CALCRL expression and the clinical features and prognosis of AML, AML/ETO+ AML patients were enrolled in the present study, taking the advance of the AML1/ETO fusion gene as the biomarker of AML in these patients. The gene discussed is RUNX1; the disease is acute myeloid leukemia.